title: Development of a rapid and sensitive LC-MS/MS assay for the determination of combretastatin A4 phosphate, combretastatin A4 and combretastatin A4 glucuronide in beagle dog plasma and its application to a pharmacokinetic study.
abstract: This study details the development and validation of a simple and sensitive liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for the quantification of combretastatin A-4 3-O-phosphate (CA4P), combretastatin A4 (CA4) and its main metabolite, combretastatin A4 glucuronide (CA4G), in beagle dog plasma. Sample pretreatment includes simple protein precipitation by adding methanol to the plasma sample containing an internal standard (colchicine). LC separation was successfully accomplished on a Waters RP8 Symmetryshield column (3.0mmx150mm, i.d., 5microm) with a gradient mobile phase of methanol (0.1% formic acid, v/v) and water (20mM ammonium acetate) at a flow rate 0.8mLmin(-1). The three analytes were detected in the positive/negative ion alternate mode, negative ion mode for CA4G and positive ion mode for CA4P and CA4. Multiple reaction monitoring (MRM) was used for determination of three analytes. Calibration curves were linear in the concentration range of 5-5000ngmL(-1) for CA4P (r>or=0.999), 5-3000ngmL(-1) for CA4 (r>or=0.999) and 5-5000ngmL(-1) for CA4G (r>or=0.999). All the validation data, such as accuracy, precision, and inter-day repeatability, were within the required limits. The method was reliable and has been successfully applied to a pharmacokinetic study of CA4P in beagle dogs via intravenous drop infusion at dose rates of 1, 3 and 9mgkg(-1). After daily intravenous drop infusions at 1mgkg(-1) for 7 consecutive days, the accumulation ratio was approximately 1.0, indicating no accumulation from multiple doses in beagles.
authors.affiliation: State Key Laboratory of Pathogen and Biosecurity, Beijing 100071, PR China; Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, Shanghai 200433, PR China.
authors.forename: Xiaojing
authors.initials: X
authors.lastname: Wang
authors.forename: Zhihang
authors.initials: Z
authors.lastname: Chen
authors.forename: Jinjing
authors.initials: J
authors.lastname: Che
authors.forename: Qingfang
authors.initials: Q
authors.lastname: Meng
authors.forename: Chengqi
authors.initials: C
authors.lastname: Shan
authors.forename: Yunan
authors.initials: Y
authors.lastname: Hou
authors.forename: Xiaolei
authors.initials: X
authors.lastname: Liu
authors.forename: Yifeng
authors.initials: Y
authors.lastname: Chai
authors.forename: Yuanguo
authors.initials: Y
authors.lastname: Cheng
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000097:blood* / Q000737:chemistry / Q000493:pharmacokinetics; D002853:Chromatography, Liquid / Q000379:methods*; D004285:Dogs; D011897:Random Allocation; D012680:Sensitivity and Specificity; D013267:Stilbenes / Q000097:blood* / Q000737:chemistry / Q000493:pharmacokinetics; D053719:Tandem Mass Spectrometry / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D013267:Stilbenes; C058728:fosbretabulin